The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT) is offering this grant to expand and enhance access to Medication-Assisted Treatment (MAT) services for individuals with opioid use disorder. This grant is for the purpose of increasing MAT availability in states most affected by high opioid and heroin admission rates. It aims to boost MAT admissions, promote integrated care delivery—combining FDA-approved medications with behavioral therapies—and significantly reduce illicit opioid and non-prescribed prescription opioid use. The program supports comprehensive, person-centered treatment, including screening, assessment, and case management, ensuring a holistic approach to recovery and sustained abstinence from opioids. This initiative targets improved public health outcomes by broadening effective treatment options.
Opportunity ID: 294189
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | TI-17-017 |
| Funding Opportunity Title: | Targeted Capacity Expansion: Medication Assisted Treatment – Prescription Drug and Opioid Addiction (Short Title: MAT-PDOA) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 93.243 — Substance Abuse and Mental Health Services_Projects of Regional and National Significance |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 31, 2017 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Jul 31, 2017 |
| Current Closing Date for Applications: | Jul 31, 2017 |
| Archive Date: | Aug 30, 2017 |
| Estimated Total Program Funding: | $28,000,000 |
| Award Ceiling: | $2,000,000 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | As the 2017 Omnibus requires, eligibility is limited to the states with the highest rates of admissions, including those that have demonstrated a dramatic increase in admissions for the treatment of opioid use disorder. See Appendix E for a list of eligible states. The application must be submitted by the Single State Agency (SSA) for Substance Abuse within the state. FY 2015 MAT-PDOA grantees funded under announcement TI-15-007 and FY 2016 MAT-PDOA grantees funded under announcement TI-16-014 are not eligible to apply for this program. |
Additional Information
| Agency Name: | Substance Abuse and Mental Health Services Adminis |
| Description: | The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), is accepting applications for fiscal year (FY) 2017 Targeted Capacity Expansion: Medication Assisted Treatment – Prescription Drug and Opioid Addiction (MAT-PDOA) grants. The purpose of this program is to expand/enhance access to medication-assisted treatment (MAT) services for persons with an opioid use disorder seeking or receiving MAT. This program targets states identified with having the highest rates of primary treatment admissions for heroin and opioids per capita and includes those with the most dramatic increases for heroin and opioids, as identified by SAMHSA’s Treatment Episode Data Set (TEDS): 2007 – 2014. The desired outcomes include: 1) an increase in the number of admissions for MAT; 2) an increase in the number of clients receiving integrated care/treatment; 3) a decrease in illicit opioid drug use at six-month follow-up; and 4) a decrease in the use of prescription opioids in a non-prescribed manner at six-month follow-up. For the purpose of this FOA, integrated care/treatment is defined as the organized delivery and/or coordination of medical (including the use of Food and Drug Administration (FDA)-approved drugs [buprenorphine, methadone, extended release injectable naltrexone] for addiction), behavioral, social, peer, and other recovery support services provided to individual patients who have multiple healthcare needs in order to produce better overall health outcomes. MAT is defined as the use of FDA-approved opioid agonist medications (e.g., methadone, buprenorphine products, including buprenorphine/naloxone combination formulations and buprenorphine mono-product formulations) for the maintenance treatment of opioid use disorder and opioid antagonist medication (e.g., extended-release) in combination with behavioral therapies to prevent relapse to opioid use. MAT includes screening, assessment (which includes determination of severity of opioid use disorder, including presence of physical dependence and appropriateness for MAT), and case management. MAT is to be provided in combination with comprehensive opioid use disorder treatment, including but not limited to: counseling, behavioral therapies, other clinically appropriate services in order for individuals to achieve and maintain abstinence from all opioids and heroin, and, when needed, pharmacotherapy for co-occurring alcohol use disorder. MAT is to be provided in a clinically driven, person-centered, and individualized setting. |
| Link to Additional Information: | Targeted Capacity Expansion: Medication Assisted Treatment – Prescription Drug and Opioid Addiction (Short Title: MAT-PDOA) |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Eileen Bermudez
Office of Financial Resources, Division of Grants Management Substance Abuse and Mental Health Services Administration (240) 276-1412 Email:FOACSAT@samhsa.hhs.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | Eileen Bermudez Office of Financial Resources, Division of Grants Management Substance Abuse and Mental Health Services Administration (240) 276-1412 Email: FOACSAT@samhsa.hhs.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.243 | TI-17-017 | MAT-PDOA | PKG00232852 | May 31, 2017 | Aug 03, 2017 | View |
Package 1
Mandatory forms
294189 SF424_2_1-2.1.pdf
294189 SF424A-1.0.pdf
294189 HHS_CheckList_2_1-2.1.pdf
294189 PerformanceSite_2_0-2.0.pdf
294189 Project-1.1.pdf
294189 Budget-1.1.pdf
294189 SF424B-1.1.pdf
294189 OtherNarrativeAttachments_1_2-1.2.pdf
Optional forms
294189 SFLLL_1_2-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
